Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
News|Webcasts|May 8, 2026
How Quest Diagnostics Is Revolutionizing Patient Recruitment With Data and Precision
Author(s)Quest Diagnostics
Webinar Date/Time: Thu, May 28, 2026 1:00 PM EDT
Struggling to find the right patients for your clinical trials in the era of precision medicine? Register for this webinar to discover how to leverage data-driven strategies to identify, reach, and recruit clinically eligible patients more effectively than ever before.
Register Free:
Finding clinically eligible patients for targeted therapies remains one of the top barriers, causing significant delays in clinical trial timelines. This webinar introduces a new, data-driven approach that leverages deep patient insights to overcome these recruitment hurdles. The session features a comparison of patient identification and outreach methods, weighing their effectiveness on crucial factors like cost and precision. Participants will leave with a better understanding of why a targeted recruitment approach maximizes impact, and why Quest should be an essential addition to their recruitment mix.
Key Learning Objectives
- See how data-driven insights accelerate clinical trial recruitment.
- Evaluate recruitment methods on cost, precision and patient access.
- Learn how Quest helps recruit highly qualified patients for clinical trials
Who Should Attend
- Pharmaceutical clinical trial personnel, CRO clinical trial personnel, clinical trial planning and recruitment personnel
Speaker:
Steve Schlachter, MBA
Product Director, Healthcare Analytics Solutions
Quest Diagnostics
Register Free:
Related to this article
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, outlines what it takes to move beyond transactional engagement and treat patient advocacy organizations as long-term partners in the science and the care.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, describes how shifting patient engagement from protocol review to endpoint selection transforms both the quality of trial data and the experience of participation.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
Participant engagement depends more on clarity and understanding than on gamification or incentives, requiring engagement embedded into trial workflows as a core design component rather than a peripheral consideration
Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Joseph Geraci, PhD, co-founder and chief scientific and technical officer at NetraMark, about why explainable AI, not black-box prediction, is needed to reveal clinically meaningful patient subgroups in regulated drug development.